Structure of AKBA
CAS No.: 67416-61-9
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
AKBA (Acetyl-11-keto-β-boswellic acid) is an active compound extracted from frankincense and a novel activator of Nrf2. AKBA can be used in research on inflammatory diseases and cancer.
Synonyms: Acetyl-11-keto-β-boswellic acid; 3-O-acetyl-11-keto-β-Boswellic acid; Acetylketo-β-boswellic acid
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 67416-61-9 |
| Formula : | C32H48O5 |
| M.W : | 512.72 |
| SMILES Code : | C[C@@]([C@@](C1=C2)(CC[C@@](C)(CC[C@H]3C)[C@@]1([H])[C@H]3C)C)(CC[C@@]4([H])[C@@]5(C)C(O)=O)[C@@](C2=O)([H])[C@]4(CC[C@H]5OC(C)=O)C |
| Synonyms : |
Acetyl-11-keto-β-boswellic acid; 3-O-acetyl-11-keto-β-Boswellic acid; Acetylketo-β-boswellic acid
|
| MDL No. : | MFCD03788777 |
| InChI Key : | HMMGKOVEOFBCAU-BCDBGHSCSA-N |
| Pubchem ID : | 11168203 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| Mouse primary keratinocytes | 20 μM | 12 h | AKBA decreases H3K27me3 methylation level | EBioMedicine. 2019 Jan;39:575-590 |
| HaCaT cells | 20 μM | 12 h | AKBA inhibits MAT2A function, decreases SAM level and SAM/SAH ratio | EBioMedicine. 2019 Jan;39:575-590 |
| U87-MG cells | 10 mM, 20 mM, 30 mM | 24 h | To detect the inhibitory effect of AKBA on autophagy in U87-MG cells using transmission electron microscopy. Results showed that AKBA significantly inhibited autophagy in U87 cells. | Acta Pharm Sin B. 2020 Feb;10(2):301-312 |
| HEK293 cells | 25 μM | 180 min | AKBA significantly increased the formation of 15-LOX products in cells expressing 15-LOX-1 and 15-LOX-2. | Adv Sci (Weinh). 2023 Feb;10(6):e2205604 |
| M2-MDMs | 10 μM | 180 min | AKBA significantly increased the formation of 12/15-LOX-derived lipid mediators and SPMs, particularly in M2-MDMs. | Adv Sci (Weinh). 2023 Feb;10(6):e2205604 |
| Human monocytes | 10 μM | 90 min | AKBA significantly elevated the levels of 15-LOX and 12-LOX products and increased the formation of SPMs, especially in M2-MDMs. | Adv Sci (Weinh). 2023 Feb;10(6):e2205604 |
| M1-like macrophages | 10 μM | 90 min | AKBA significantly reduced the formation of LTB4 while increasing the production of 12-HETE. | Nat Chem Biol. 2020 Jul;16(7):783-790 |
| Neutrophils | 10 μM | 90 min | AKBA significantly reduced the levels of 5-HETE and LTB4 while increasing the production of 12-HETE. | Nat Chem Biol. 2020 Jul;16(7):783-790 |
| HEK293 cells | 25 μM | 15 min | AKBA significantly reduced the formation of 5-LOX products (e.g., 5-HETE and LTB4) while increasing the production of 12-HETE. | Nat Chem Biol. 2020 Jul;16(7):783-790 |
| Human prostate cancer cells (PC-3) | 50μM | AKBA inhibited PC-3 cell proliferation, requiring a higher concentration than that needed to suppress endothelial cell proliferation. | Cancer Res. 2009 Jul 15;69(14):5893-900 | |
| Human umbilical vascular endothelial cells (HUVECs) | 5-10 μM | 6-8 h | AKBA significantly suppressed or terminated VEGF-induced tubular formation of endothelial cells. | Cancer Res. 2009 Jul 15;69(14):5893-900 |
| Human umbilical vascular endothelial cells (HUVECs) | 1-5 μM | 24 h | AKBA inhibited VEGF-induced HUVEC migration and invasion in a dose-dependent manner. | Cancer Res. 2009 Jul 15;69(14):5893-900 |
| U87-MG human glioblastoma cells | 10, 20, 30 μM | 24 and 48 h | AKBA inhibited cell proliferation, caused the release of LDH, decreased DNA synthesis, and inhibited the migration, invasion, and colony formation of U87-MG human glioblastoma cells. | J Exp Clin Cancer Res. 2018 Jul 3;37(1):132 |
| U251 human glioblastoma cells | 10, 20, 30 μM | 24 and 48 h | AKBA inhibited cell proliferation, caused the release of LDH, decreased DNA synthesis, and inhibited the migration, invasion, and colony formation of U251 human glioblastoma cells. | J Exp Clin Cancer Res. 2018 Jul 3;37(1):132 |
| PC3 cells | 5, 10, 20, 30, 40 μM | 48 h | AKBA dose-dependently inhibited cell proliferation in PC3 cells, with an IC50 value of approximately 21μM. | Acta Pharmacol Sin. 2019 May;40(5):689-698 |
| PC3/Doc cells | 5, 10, 20, 30, 40 μM | 48 h | AKBA dose-dependently inhibited cell proliferation and induced cell apoptosis in docetaxel-resistant PC3/Doc cells, with an IC50 value of approximately 17μM in anti-proliferation. | Acta Pharmacol Sin. 2019 May;40(5):689-698 |
| LS174T cells | 20 μM | 72 h | AKBA inhibited growth of LS174T cells, resulting in a 40-50% reduction in cell numbers. | Br J Pharmacol. 2006 Aug;148(8):1099-107 |
| HT-29 cells | 30 μM | 72 h | AKBA inhibited growth of HT-29 cells, resulting in a 40-50% reduction in cell numbers. | Br J Pharmacol. 2006 Aug;148(8):1099-107 |
| HCT-116 cells | 5-25 μM | 24-72 h | AKBA inhibited cellular growth in a time- and dose-dependent manner in HCT-116 cells, leading to G1 phase cell cycle arrest accompanied by downregulation of cyclin D1, E, CDK2, CDK4, and phosphorylated Rb, and upregulation of p21 expression. | Br J Pharmacol. 2006 Aug;148(8):1099-107 |
| Schwann cells | 2 µg/mL | 0, 6, 12, 24 h | AKBA treatment significantly increased p-ERK1/2 expression in a time-dependent manner. | Neural Regen Res. 2018 Mar;13(3):484-491 |
| Schwann cells | 1.25, 2.5, 5, 10, 20 µg/mL | 24 h | AKBA significantly promoted SC proliferation at concentrations of 1.25–5 µg/mL, peaking at 2 µg/mL; inhibited proliferation at >5 µg/mL. | Neural Regen Res. 2018 Mar;13(3):484-491 |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| BALB/c nude mice | Orthotopic U87-MG glioblastoma model | Oral administration | 100 mg/kg, 200 mg/kg | Once daily for 21 days | To evaluate the anti-tumor effects of AKBA on orthotopic glioblastoma. MRI results showed that AKBA significantly inhibited tumor growth without obvious weight loss or abnormal behavior. | Acta Pharm Sin B. 2020 Feb;10(2):301-312 |
| BALB/c-nu nude mice | U87-MG human glioblastoma xenograft model | Oral | 100 mg/kg | Once daily for 14 days | Oral administration of AKBA significantly suppressed the tumorigenicity of U87-MG cells in a xenograft mouse model. | J Exp Clin Cancer Res. 2018 Jul 3;37(1):132 |
| C57BL/6 mice | RM-1/Doc homograft model | Intraperitoneal injection | 30 mg/kg | Once daily for 14 days | AKBA significantly suppressed the growth of RM-1/Doc homografts without decreasing body weight. | Acta Pharmacol Sin. 2019 May;40(5):689-698 |
| BALB/cA nude mice | Human prostate tumor xenograft model | Subcutaneous injection | 10 mg/kg | Once daily for 30 days | AKBA significantly suppressed tumor volume and weight growth and inhibited tumor angiogenesis. | Cancer Res. 2009 Jul 15;69(14):5893-900 |
| Sprague-Dawley rats | Sciatic nerve injury model | Intraperitoneal injection | 1.5, 3, 6 mg/kg | Once every 2 days for 30 days | 3 and 6 mg/kg AKBA significantly increased sciatic nerve index, Cuadros index of triceps muscle, p-ERK1/2 expression, and S100 immunoreactivity. | Neural Regen Res. 2018 Mar;13(3):484-491 |
| Mice | Zymosan-induced peritonitis | Intraperitoneal injection | 20 mg/kg | Single dose, lasting 24 hours | AKBA significantly elevated SPM levels and promoted the resolution of inflammation. | Adv Sci (Weinh). 2023 Feb;10(6):e2205604 |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.95mL 0.39mL 0.20mL |
9.75mL 1.95mL 0.98mL |
19.50mL 3.90mL 1.95mL |
|
Tags: AKBA | Acetyl-11-keto-β-boswellic acid | HIF/HIF Prolyl-Hydroxylase | Reactive Oxygen Species | Endogenous Metabolite | Hypoxia-inducible factors | HIFs | HIF-PH | inhibitor | 67416-61-9 |
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


